基于前列腺特异性膜抗原（PSMA）的放射性配体疗法在前列腺癌中日益重要的作用综述

Review on the Increasing Role for PSMA-Based Radioligand Therapy in Prostate Cancer.

作者信息

von Eyben Finn Edler, Virgolini Irene, Baum Richard

机构信息

Center of Tobacco Control, 5230 Odense, Denmark.

Department of Nuclear Medicine, University Hospital Innsbruck, 6020 Innsbruck, Austria.

出版信息

Cancers (Basel). 2024 Jul 12;16(14):2520. doi: 10.3390/cancers16142520.

UNLABELLED

In 2021, two randomized controlled trials (RCTs), TheraP and VISION, demonstrated that Lu-PSMA-617 as monotherapy was more effective for the decline of PSA than the comparator third-line treatments.

METHODS

Our review summarizes new RCTs that add to the use of radioligand therapy (RLT) for patients with high-risk prostate cancer (PCa).

RESULTS

Four past and present RCTs included 1081 patients. An RCT, ENZA-p, studied first-line treatment of patients with metastatic castration-resistant PCa (mCRPC). A combination of enzalutamide (ENZA) and Lu-PSMA-617 gave longer progression-free survival than ENZA as monotherapy. Other RCTs of patients with mCRPC, including the PSMAfore, and SPLASH trials, showed Lu-PSMA-617 as second-line treatment gave better progression-free survival than androgen receptor pathway inhibitors (combined value < 6.9 × 10).

CONCLUSIONS

Patients with PCa gain if they are given PSMA-RLT early in the treatment of PCa and as part of combination therapies.

未标注

2021年，两项随机对照试验（RCT），即TheraP和VISION试验，表明镥-PSMA-617作为单一疗法在降低前列腺特异性抗原（PSA）方面比对照三线治疗更有效。

方法

我们的综述总结了新的随机对照试验，这些试验增加了放射性配体疗法（RLT）在高危前列腺癌（PCa）患者中的应用。

结果

四项过去和现在的随机对照试验纳入了1081名患者。一项随机对照试验ENZA-p研究了转移性去势抵抗性前列腺癌（mCRPC）患者的一线治疗。恩杂鲁胺（ENZA）和镥-PSMA-617联合使用比单独使用ENZA的无进展生存期更长。其他mCRPC患者的随机对照试验，包括PSMAfore和SPLASH试验，表明镥-PSMA-617作为二线治疗比雄激素受体通路抑制剂的无进展生存期更好（合并值<6.9×10）。